Tailwinds Drive Lilly Growth, But Headwinds Remain
This article was originally published in Scrip
Eli Lilly & Co. investors were somewhat enthusiastic on Jan. 5 about the big pharma company's forecast for growth in 2016 even though Lilly's guidance for $20.2bn to $20.7bn in revenue and $3.45 to $3.55 in earnings per share (EPS) fell below Wall Street analysts' expectations, due to well-known challenges that could moderate tailwinds driving revenue and earnings gains this year.
You may also be interested in...
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.